<SEC-DOCUMENT>0001193125-23-154688.txt : 20230526
<SEC-HEADER>0001193125-23-154688.hdr.sgml : 20230526
<ACCEPTANCE-DATETIME>20230526061052
ACCESSION NUMBER:		0001193125-23-154688
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230526
FILED AS OF DATE:		20230526
DATE AS OF CHANGE:		20230526

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		23962922

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d491663d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated May&nbsp;26, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d491663dex991.htm">Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: May&nbsp;26, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d491663dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g491663dsp4.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Announces Publication of Abstracts for&nbsp;ASCO&nbsp;2023 Annual Meeting </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New data published from Part C of <FONT STYLE="white-space:nowrap">TACTI-002</FONT> Phase II Trial evaluating
eftilagimod alpha plus pembrolizumab in metastatic 2nd line head and neck squamous cell carcinoma </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Deep, durable responses seen across all <FONT STYLE="white-space:nowrap">PD-L1</FONT> subgroups with a 13.5%
Complete Response rate and median Duration of Response not yet reached (minimum <FONT STYLE="white-space:nowrap">follow-up</FONT> of 17 months) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the overall patient population, regardless of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression, a
strong response rate of 29.7% and <FONT STYLE="white-space:nowrap">12-month</FONT> overall survival rate of 46.0% were achieved </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In patients with a <FONT STYLE="white-space:nowrap">PD-L1</FONT> Combined Positive Score of &#8805;20, a very
promising response rate of 60% and <FONT STYLE="white-space:nowrap">12-month</FONT> overall survival rate of 66.7% were achieved </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Treatment was safe and well tolerated with no new safety signals </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">More mature and final data will be presented during the poster session at ASCO 2023 </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 26</B><B></B><B>&nbsp;May </B><B>2023 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the
Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces data from Part C of its
<FONT STYLE="white-space:nowrap">TACTI-002</FONT> Phase II trial has been published in an abstract available on the 2023 American Society of Clinical Oncology&#146;s (ASCO) Annual Meeting&#146;s official website. A Trial
in&nbsp;Progress&nbsp;abstract for the Phase II/III <FONT STYLE="white-space:nowrap">AIPAC-003</FONT> trial has also been published. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT
STYLE="white-space:nowrap">TACTI-002</FONT> poster will contain more mature (longer follow up) and final data that is not part of the abstract and will be available on the <U>Posters&nbsp;&amp; Publication section</U> of Immutep&#146;s website after
its presentation at ASCO. Abstracts are available at&nbsp;<U>ASCO.org</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U><FONT STYLE="white-space:nowrap">TACTI-002</FONT> Abstract </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Title</B>: <I>Final results from <FONT STYLE="white-space:nowrap">TACTI-002</FONT> Part C: A Phase II study of eftilagimod alpha (soluble <FONT
STYLE="white-space:nowrap">LAG-3</FONT> protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for <FONT STYLE="white-space:nowrap">PD-L1</FONT></I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Poster Session: Head and Neck Cancer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date and Time: 5&nbsp;June
2023, <FONT STYLE="white-space:nowrap">2:15PM-5:15PM</FONT> EDT </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Presenter: Dr.&nbsp;Bernard Doger, START
<FONT STYLE="white-space:nowrap">Madrid-FJD,</FONT> Fundaci&oacute;n Jim&eacute;nez D&iacute;az University Hospital, Madrid, Spain </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abstract #: <U>6029</U>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U><FONT STYLE="white-space:nowrap">AIPAC-003</FONT> Abstract </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Title:</B><I><FONT STYLE="white-space:nowrap">&nbsp;AIPAC-003:</FONT> A randomized, double-blind, placebo-controlled phase 3 trial
testing</I><I></I><I>&nbsp;eftilagimod</I><I></I><I>&nbsp;alpha (soluble <FONT STYLE="white-space:nowrap">LAG-3)</FONT> in <FONT STYLE="white-space:nowrap">HER2-neg/low</FONT> metastatic breast cancer patients receiving paclitaxel, following an
open-label dose optimization.</I> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Poster Session: Breast Cancer &#150; Local/Regional/Adjuvant </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date and Time: 4&nbsp;June 2023, <FONT STYLE="white-space:nowrap">9:00AM-12:00PM</FONT> EDT </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Presenter: Dr.&nbsp;Nuhad&nbsp;K. Ibrahim, Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson
Cancer Center, Houston, TX </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abstract #: <U>TPS1120</U> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g491663dsp4.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alpha (Efti) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist that stimulates both innate and
adaptive immunity for the treatment of cancer. As a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex)
Class&nbsp;II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like <FONT
STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and CXCL10 that further boost the immune system&#146;s ability to fight cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck
squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy
and/or chemotherapy. Efti has received Fast Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States Food and Drug Administration (FDA). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical stage biotechnology
company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT
STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its
expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>cstrong@citadelmagnus.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and
Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000<U>; chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the CEO of Immutep Limited. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;33, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g491663dsp4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491663dsp4.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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ME<QK+!<VT\1*RQ/&P((/MU%9-.+M:S709I4@"@ H * "@ H * "@ H * "@
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M+VL_SM>S\B\/Y5>WR+7Y!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % '!WOPO^'E[H/CGPT?!OAVST?XE'6)/'EOI.DV6CR>*KS7K,Z?JVJZW<Z7
M#!-?ZU<6NU6U&61KK,4;"4-&A6E*2<7=^[:WE;;Y>06MY'E?BR_L?V;?AUXE
M\3VIUSQSKFO>)+#4]<U?Q#<Z3:ZCKWB*?0]%\+6^JZNWAW1-.TVS6/0_#&C0
M.MAI=JLS6?F2JUS=3SRDI7MHHJ*LDNFK?5M[L%H6OV>_C/??&31-9OM2T2/1
M[[0M1@LIS9RS2Z;=)=P27$#6YN%WQ3QK'MDB+RX#0R;OWVT2!]#4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MZ3+%_9]_, 3]HN=-E01^=N9R3$T6XLS-EG.//Q&64*VL:DZ;>ZCMVV_'UO\
M/Y['\.X7%N4X5)T76_B1C91NERJR\XI=M;G(Z/\ LL^%[*Z2?6-;U36H8V#?
M8DBATR"4#'RSRQ22S,IQR(WB)R1NK&CE%"C-/FE.W5GG8?@K+J<X2KU:E2--
MWC!VY=-KZGTEI.CZ=H=C#INE6-K86-N,0VMI%'!#&,#.%C498G)+'+,2222<
MUZL(4Z:2A'E2\CZVE2IX>"I8>C"A3CLHZ?-^?^1J#CVQ_2G^AJE8* "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M]EF7"674\%5EAH-5J2YDV[;(X3]E[Q%=6OB35O#)E<V6HZ:VH10$DQQ7FGO
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M#J2:OK^KZ\EQ%)KTJ2"X-E:&Y42W[W4J[)9$3RXX]^6WA$8 _6Z,;45<;=O
M  7 !^48' P,=* 'T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M(-DB1R+G[CA67H<?*>.F>W;VI#&);6D/^JA@A]/+1(_I@H!0!, B],#&,<]
M. /ID4 !"GJ>@]< 8Y]?\\>@H A6VM$<R)# LC9W.L<:N<]<N "?Q- $X"Q]
M]N>.3Z=, GW[4 -*(>& Y!Z\< 8/'H,_K0!!'9V,+;XK:UC=<Y=(HD?C@[F5
M0<Y'K0!8157[I_(YQCC^8Z^U 'XO_$[_ ).#\4?]E,D_]/MMQ0!^SAMX&8.T
M2%E/#%%+#&<8)!Q^&* )@H7IV_3';Z?X4 +0 4 % !0 4 % !0 4 % !0 4
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MR#+\V" 2:W?_ /"6W/P]N[32+75+75--UZ_?1]5OI-/@MYD@TC_C\:*SN_\
M3K*:2>$Q^261_-"D,O(!9NM%UKP_X-N-0DN]NJ^&;O6/$^EVL5_J%]8PV41O
M;E?#4M[>0I/J&GMI4DMF)98%,#-%+!$HM844 [?PII4FG:>;JZN'N]2UAQJV
MJW+23-$;RZ1&$%G%*Q^RZ?;0"&V@A7&([=6?=*\CN ?D+\3CC]H/Q3V ^)C>
MV-VNVVW\^U '[1#I_G\* %H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M4# P.,?AB@!: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M #[7_@/_  0_X:D\>?\ 0(\+_P#@)JO_ ,MZ/[:K?R+[O^"'^N>-_P"?:_\
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M_GVO_ ?^"'_#4GCS_H$>%_\ P$U7_P"6]']M5OY%]W_!#_7/&_\ /M?^ _\
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M)JO_ ,MZ/[:K?R+[O^"'^N>-_P"?:_\  ?\ @A_PU)X\_P"@1X7_ / 35?\
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M_P#/M?\ @/\ P0_X:D\>?] CPO\ ^ FJ_P#RWH_MJM_(ON_X(?ZYXW_GVO\
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M:_\  ?\ @A_PU)X\_P"@1X7_ / 35?\ Y;T?VU6_D7W?\$/]<\;_ ,^U_P"
M_P#!#_AJ3QY_T"/"_P#X":K_ /+>C^VJW\B^[_@A_KGC?^?:_P# ?^"'_#4G
MCS_H$>%__ 35?_EO1_;5;^1?=_P0_P!<\;_S[7_@/_!#_AJ3QY_T"/"__@)J
MO_RWH_MJM_(ON_X(?ZYXW_GVO_ ?^"'_  U)X\_Z!'A?_P !-5_^6]']M5OY
M%]W_  0_USQO_/M?^ _\$/\ AJ3QY_T"/"__ (":K_\ +>C^VJW\B^[_ ((?
MZYXW_GVO_ ?^"'_#4GCS_H$>%_\ P$U7_P"6]']M5OY%]W_!#_7/&_\ /M?^
M _\ !#_AJ3QY_P! CPO_ . FJ_\ RWH_MJM_(ON_X(?ZYXW_ )]K_P !_P""
M'_#4GCS_ *!'A?\ \!-5_P#EO1_;5;^1?=_P0_USQO\ S[7_ (#_ ,$/^&I/
M'G_0(\+_ /@)JO\ \MZ/[:K?R+[O^"'^N>-_Y]K_ ,!_X(?\-2>//^@1X7_\
M!-5_^6]']M5OY%]W_!#_ %SQO_/M?^ _\$/^&I/'G_0(\+_^ FJ__+>C^VJW
M\B^[_@A_KGC?^?:_\!_X(?\ #4GCS_H$>%__  $U7_Y;T?VU6_D7W?\ !#_7
M/&_\^U_X#_P0_P"&I/'G_0(\+_\ @)JO_P MZ/[:K?R+[O\ @A_KGC?^?:_\
M!_X(?\-2>//^@1X7_P# 35?_ );T?VU6_D7W?\$/]<\;_P ^U_X#_P $/^&I
M/'G_ $"/"_\ X":K_P#+>C^VJW\B^[_@A_KGC?\ GVO_  '_ ((?\-2>//\
MH$>%_P#P$U7_ .6]']M5OY%]W_!#_7/&_P#/M?\ @/\ P0_X:D\>?] CPO\
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MY_T"/"__ (":K_\ +>C^VJW\B^[_ ((?ZYXW_GVO_ ?^"'_#4GCS_H$>%_\
MP$U7_P"6]']M5OY%]W_!#_7/&_\ /M?^ _\ !#_AJ3QY_P! CPO_ . FJ_\
MRWH_MJM_(ON_X(?ZYXW_ )]K_P !_P""'_#4GCS_ *!'A?\ \!-5_P#EO1_;
M5;^1?=_P0_USQO\ S[7_ (#_ ,$/^&I/'G_0(\+_ /@)JO\ \MZ/[:K?R+[O
M^"'^N>-_Y]K_ ,!_X(?\-2>//^@1X7_\!-5_^6]']M5OY%]W_!#_ %SQO_/M
M?^ _\$/^&I/'G_0(\+_^ FJ__+>C^VJW\B^[_@A_KGC?^?:_\!_X(?\ #4GC
MS_H$>%__  $U7_Y;T?VU6_D7W?\ !#_7/&_\^U_X#_P0_P"&I/'G_0(\+_\
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MD\>?] CPO_X":K_\MZ/[:K?R+[O^"'^N>-_Y]K_P'_@A_P -2>//^@1X7_\
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M>]KU7E>$_EE_X$SZ5\+Y4DVZ3E;?5IV[76J]5JAW_#/7PK_Z -S_ .#K6/\
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M2#_AGKX5_P#0!N?_  =:Q_\ )U']D8/^67_@;#_5K)/^@2?_ (/J_P#R0?\
M#/7PK_Z -S_X.M8_^3J/[(P?\LO_  -A_JUDG_0)/_P?5_\ D@_X9Z^%?_0!
MN?\ P=:Q_P#)U']D8/\ EE_X&P_U:R3_ *!)_P#@^K_\D'_#/7PK_P"@#<_^
M#K6/_DZC^R,'_++_ ,#8?ZM9)_T"3_\ !]7_ .2#_AGKX5_] &Y_\'6L?_)U
M']D8/^67_@;#_5K)/^@2?_@^K_\ )!_PSU\*_P#H W/_ (.M8_\ DZC^R,'_
M "R_\#8?ZM9)_P! D_\ P?5_^2#_ (9Z^%?_ $ ;G_P=:Q_\G4?V1@_Y9?\
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MK62?] D__!]7_P"2#_AGKX5_] &Y_P#!UK'_ ,G4?V1@_P"67_@;#_5K)/\
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M[(P?\LO_  -A_JUDG_0)/_P?5_\ D@_X9Z^%?_0!N?\ P=:Q_P#)U']D8/\
MEE_X&P_U:R3_ *!)_P#@^K_\D'_#/7PK_P"@#<_^#K6/_DZC^R,'_++_ ,#8
M?ZM9)_T"3_\ !]7_ .2#_AGKX5_] &Y_\'6L?_)U']D8/^67_@;#_5K)/^@2
M?_@^K_\ )!_PSU\*_P#H W/_ (.M8_\ DZC^R,'_ "R_\#8?ZM9)_P! D_\
MP?5_^2#_ (9Z^%?_ $ ;G_P=:Q_\G4?V1@_Y9?\ @;#_ %:R3_H$G_X/J_\
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M2#_AGKX5_P#0!N?_  =:Q_\ )U']D8/^67_@;#_5K)/^@2?_ (/J_P#R0?\
M#/7PK_Z -S_X.M8_^3J/[(P?\LO_  -A_JUDG_0)/_P?5_\ D@_X9Z^%?_0!
MN?\ P=:Q_P#)U']D8/\ EE_X&P_U:R3_ *!)_P#@^K_\D'_#/7PK_P"@#<_^
M#K6/_DZC^R,'_++_ ,#8?ZM9)_T"3_\ !]7_ .2#_AGKX5_] &Y_\'6L?_)U
M']D8/^67_@;#_5K)/^@2?_@^K_\ )!_PSU\*_P#H W/_ (.M8_\ DZC^R,'_
M "R_\#8?ZM9)_P! D_\ P?5_^2#_ (9Z^%?_ $ ;G_P=:Q_\G4?V1@_Y9?\
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MK62?] D__!]7_P"2#_AGKX5_] &Y_P#!UK'_ ,G4?V1@_P"67_@;#_5K)/\
MH$G_ .#ZO_R0?\,]?"O_ * -S_X.M8_^3J/[(P?\LO\ P-A_JUDG_0)/_P '
MU?\ Y(OZ7\#/AOHNHV.KZ?HUQ!?:9<Q7MG*=6U601W%NXDB<QRWC*P5U!PRD
I<4UEV&H.,J:E&2V?,W;T[&M#A_*J%6%2AAW3G%Z.4Y5/NYV^7U6I_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
